EN DE
Watch Guangdong Biolight Meditech Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Guangdong Biolight Meditech Co Ltd (300246) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Guangdong Biolight Meditech Co Ltd stock ¥2.64, price ¥12.83, that is 79.4% below the price, quality 46 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE1000015Q4

GB Guangdong Biolight Meditech Co Ltd logo Thin data Nov 15, 2026

Guangdong Biolight Meditech Co Ltd

300246 · SHE

Far too expensive (fair value 79% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Quality 46/100 
0.4% dividend yield · Token dividend
Fair value ¥2.64 · Strongly overvalued 
Weak Growth (revenue 5y −4.7 %/yr in CNY) 
Loss-making · -6.3% net margin (FY2025) 
Negative free cash flow 
Trails peers (2/13) 
Narrow moat 14/100 · thin data
Thin data 
Watch Guangdong Biolight Meditech Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥21.57 ¥5.31 Fair Value ¥2.64 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range ¥5.31 – ¥21.57 · fair‑value band ¥1.85 – ¥3.42 · the ¥12.83 price screens above the ¥2.64 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Guangdong Biolight Meditech Co in your weekly email

Every Wednesday you see whether Guangdong Biolight Meditech Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Guangdong Biolight Meditech Co., Ltd. engages in the research and development, production, sale, and service of medical devices products and solutions in China. It operates in two segments, Life Information and Support, and Kidney Disease.

Show moreShow less

The company offers emergency and critical care monitor, subcritical care monitor, general ward monitor, outpatient monitor, neonatal monitor, infusion pump, electrocardiograph, maternal and fetal monitor, defibrillator, multifunctional suspension device, internet of things, and central station; hemodiafiltration equipment, peritoneal dialysis equipment, liquid supply system, and hemodialysis water equipment; and finger clip oximeter, sphygmomanometer, fetal heart rate monitor, body temperature monitoring system, and home medical mall, as well as hemoperfusion devices, high throughput and low flu hemodialyzer, hemodialysis concentrate, dry powder, citric acid disinfectant, tube/puncture needle, dialysate filter, and dialysis fluid filter.

It offers its products under JUNKANG MEDICAL, BIOLIGHT HEALTHCARE, TRUSTRONG, BR Medical Service, SHENBA, HUA VUE MEDICAL, BOAO TIANSHENG, and other brand names. The company serves medical institutions through direct sales channel. It also exports its products.

The company was founded in 1993 and is headquartered in Zhuhai, China.

Stock analysis

Guangdong Biolight Meditech Co Ltd (300246) currently trades at ¥12.83, while our model-based Fair Value estimate is ¥2.64, 79% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 90/100, which puts the data coverage at low.

Scenario range: ¥1.85 (bear) to ¥3.42 (bull), the price of ¥12.83 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Guangdong Biolight Meditech Co Ltd reported revenue of 1.1B CNY in FY2025 versus 1.1B CNY in FY2021, a compound +0.1%/yr. Reported net income was −69.4M CNY in FY2025.

Key figures

Market cap 3.4B CNY (≈ $510M) Small · P/S ratio 3.18 · EPS (TTM) ¥−0.4400 · Dividend yield 0.4% · Net margin −6.3% · Return on equity −9.7% · Return on assets (EBIT) 0.2% (5-year average) · Revenue (TTM) 1.1B CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (low confidence).

What moves the price

The share trades about 41% below its 52-week high and 64% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −16% fair-value upside, at −79%, 300246 screens richer than that median.

Fair Value models

Bear ¥1.85 Fair Value ¥2.64 Bull ¥3.42
Price ¥12.83 · Downside -79.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA ¥1.85 ¥2.64 ¥3.42 67
NCAV (Graham) ¥1.90 ¥2.54 ¥3.80 54
All 2 models by family
Multiples
EV/EBITDA ¥1.85 ¥2.64 ¥3.42 67
Asset-Based
NCAV (Graham) ¥1.90 ¥2.54 ¥3.80 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 46/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 11
How much profit the company makes from its sales and capital
Quality Growth 48
Are margins and returns getting better?
Cashflow 13
Do the profits arrive as real cash?
Financial strength 76
Debt, balance sheet and risk of trouble
Investment 74
Does it invest with discipline instead of growing at any price?
Low Volatility 48
How calm the share price moves, does not count
Price momentum 38
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 62
Distance to the 52-week high, does not count
New shares 75
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+3.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.7%
Start year 2020 (pandemic). Over 10 years: +11.2% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
29.7% (2020) → −1.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

300246 screens overvalued: fair value 79% below the price. Compare with Abbott Laboratories, →

Compare Guangdong Biolight Meditech Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 401 stocks

Beats the industry median on 2/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 46 · Below median
Fair Value upside −79.4% · Bottom 25%
Profitability
Return on assets −2.8% · Below median
Net margin (12 months) −6.3% · Below median
Operating margin (12 months) −1.5% · Below median
Growth and dividend
Revenue growth (quarter YoY) 10.4% · Above median
Dividend yield (12 months) 0.4% · Bottom 25%
Balance sheet
Debt / equity 0.27× · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 2.98× · Pricier than median
P/S (12 months) 3.04× · Pricier than median
EV/EBITDA 64.1× · Priciest 25%
PEG 1.28× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)52 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)87 · sector 97
DIVIDEND (yield)8 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Guangdong Biolight Meditech Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Guangdong Biolight Meditech Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/300246

Frequently asked questions

Is Guangdong Biolight Meditech Co Ltd (300246) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of ¥2.64 versus a price of ¥12.83, about 79% lower (overvalued).
What is the fair value of 300246?
Our model-based fair value for Guangdong Biolight Meditech Co Ltd is ¥2.64 (as of Nov 15, 2026), built from audited fundamentals. The current price: ¥12.83.
What is the quality score of 300246?
Guangdong Biolight Meditech Co Ltd has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Guangdong Biolight Meditech Co Ltd (300246)?
Our model-based price target is the fair value of ¥2.64 (as of Nov 15, 2026) from 2 valuation models. Cautious scenario ¥1.85, optimistic scenario ¥3.42. It is a calculation from audited fundamentals, not an analyst target.
What is the Guangdong Biolight Meditech Co Ltd stock forecast for 2026?
Our models put fair value at ¥2.64, about 79% lower versus a price of ¥12.83 (overvalued). Cautious scenario ¥1.85, optimistic scenario ¥3.42. The calculation is refreshed regularly with new filings.
What is the revenue of Guangdong Biolight Meditech Co Ltd (300246)?
Guangdong Biolight Meditech Co Ltd reported trailing-twelve-month revenue of about 1.1B CNY (latest available figure, as of Nov 15, 2026).
Does Guangdong Biolight Meditech Co Ltd pay a dividend?
Guangdong Biolight Meditech Co Ltd currently shows a dividend yield of 0.39% relative to its recent price (as of Nov 15, 2026).
How much is the dividend of Guangdong Biolight Meditech Co Ltd (300246) and when is the ex-dividend date?
Guangdong Biolight Meditech Co Ltd pays a dividend of ¥0.05 per share a year, a dividend yield of 0.4%. The last ex-dividend date was Nov 26, 2025. Our assessment: Token dividend. At a yield of 0.4% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.4% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Guangdong Biolight Meditech Co Ltd (300246)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Guangdong Biolight Meditech Co Ltd it is ¥2.64 per share (as of Nov 15, 2026), against a price of ¥12.83. It is the blended result of 2 valuation models in 2 families (Multiples, Asset-Based).
Is Guangdong Biolight Meditech Co Ltd stock overvalued or undervalued in 2026?
As of Nov 15, 2026, 300246 trades above its calculated fair value: price ¥12.83, fair value ¥2.64, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300246?
No. The price is what the market pays today (¥12.83); the fair value is what the company's own numbers justify (¥2.64). For Guangdong Biolight Meditech Co Ltd the two are ¥10.19 per share apart. That gap is exactly why we show both numbers side by side.
How much is Guangdong Biolight Meditech Co Ltd worth?
The market values Guangdong Biolight Meditech Co Ltd at about 3.4B CNY (market capitalisation, as of Nov 15, 2026). Per share that is ¥12.83; our models calculate a fair value of ¥2.64 per share.
What do the bullish and bearish scenarios say about 300246?
Our models span a range for Guangdong Biolight Meditech Co Ltd: cautious scenario ¥1.85, base ¥2.64, optimistic ¥3.42 per share (as of Nov 15, 2026, price ¥12.83). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of 300246?
The PEG ratio of Guangdong Biolight Meditech Co Ltd is 1.28 (P/E divided by earnings growth, as of Nov 15, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Guangdong Biolight Meditech Co Ltd (300246)?
Balance-sheet figures for Guangdong Biolight Meditech Co Ltd (as of Nov 15, 2026): return on equity −9.7%, debt of 0.27 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 300246 from its 52-week high?
Guangdong Biolight Meditech Co Ltd trades at ¥12.83, about 41% below its 52-week high of ¥21.57 and 64% above the low of ¥7.83 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ¥2.64 is for.
Which stocks are comparable to Guangdong Biolight Meditech Co Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Guangdong Biolight Meditech Co Ltd stock attractive at the current price?
The data as of Nov 15, 2026: price ¥12.83, calculated fair value ¥2.64 (−79%), Quality Score 46/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300246 calculated?
We run Guangdong Biolight Meditech Co Ltd through 2 models from 2 families: Multiples, Asset-Based. Every model gets the same audited fundamentals; the fair value of ¥2.64 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Guangdong Biolight Meditech Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Guangdong Biolight Meditech Co Ltd (300246)?
The closing price on Nov 16, 2026 was ¥12.83. Our model-based fair value is ¥2.64, about 79% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Guangdong Biolight Meditech Co Ltd right now?
The price sits above even our optimistic bull case (¥3.42). The favourable scenario is already priced in. Weak quality (46/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (¥1.85 to ¥3.42) leaves room in how you read the outcome.

Key figures of Guangdong Biolight Meditech Co Ltd

How large is the market capitalisation of Guangdong Biolight Meditech Co Ltd (300246)?
The market capitalisation of Guangdong Biolight Meditech Co Ltd is 3.4B CNY (≈ $510M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Guangdong Biolight Meditech Co Ltd (300246)?
The price-to-sales ratio of Guangdong Biolight Meditech Co Ltd is 3.18 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Guangdong Biolight Meditech Co Ltd (300246)?
Earnings per share at Guangdong Biolight Meditech Co Ltd are ¥−0.4400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Guangdong Biolight Meditech Co Ltd (300246)?
The dividend yield of Guangdong Biolight Meditech Co Ltd is 0.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Guangdong Biolight Meditech Co Ltd (300246)?
The net margin of Guangdong Biolight Meditech Co Ltd is −6.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Guangdong Biolight Meditech Co Ltd (300246)?
The return on equity (ROE) of Guangdong Biolight Meditech Co Ltd is −9.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Guangdong Biolight Meditech Co Ltd (300246)?
On an EBIT basis the return on assets of Guangdong Biolight Meditech Co Ltd is 0.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Guangdong Biolight Meditech Co Ltd (300246)?
Revenue at Guangdong Biolight Meditech Co Ltd is growing 10.4% versus a year earlier (3y avg −2.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Guangdong Biolight Meditech Co Ltd (300246)?
Earnings per share at Guangdong Biolight Meditech Co Ltd are growing 299% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Guangdong Biolight Meditech Co Ltd (300246) generate?
The free cash flow of Guangdong Biolight Meditech Co Ltd is −77.0M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Guangdong Biolight Meditech Co Ltd (300246) carry?
The net debt of Guangdong Biolight Meditech Co Ltd is 132M CNY (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Guangdong Biolight Meditech Co Ltd in the live analysis

One click puts Guangdong Biolight Meditech Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.